<DOC>
	<DOCNO>NCT01924325</DOCNO>
	<brief_summary>Nondisabling cerebrovascular event represent large group cerebrovascular disease high risk recurrent stroke . A recent trial indicate clopidogrel aspirin treatment reduce risk recurrent stroke associate increased hemorrhage event , compare aspirin monotherapy . Apixaban , new oral anticoagulant , prove effective traditional anticoagulant less risk bleed event . To estimate whether apixaban beneficial acute TIA minor stroke , randomize , double-blind , multicenter , control clinical trial design . The investigator assess hypothesis 21-days apixaban regimen superior clopidogrel aspirin dual-therapy treatment high-risk patient acute nondisabling cerebrovascular event .</brief_summary>
	<brief_title>Apixaban Versus Dual-antiplatelet Therapy ( Clopidogrel Aspirin ) Acute Non-disabling Cerebrovascular Events</brief_title>
	<detailed_description>The ADANCE study randomize , double-blind clinical trial target enrollment 3,000 Chinese patient . Two subtypes patient enrol : I , acute disable ischemic stroke ( &lt; 24 hour symptom onset ) ; II , acute TIA ( &lt; 24 hour symptom onset ) . Patients randomize 3 group : Ⅰ Receiving 75 mg dose clopidogrel 75mg dose aspirin day 1 day 21 , placebo apixaban twice daily . Ⅱ Receiving 2.5-mg twice daily apixaban , placebo clopidogrel placebo aspirin day 1 day 21 . Ⅲ Receiving 5-mg twice daily apixaban , placebo clopidogrel placebo aspirin day 1 day 21 . From day 22 3 month , patient receive 75-mg dose clopidogrel long-term antiplatelet therapy . The primary efficacy end point percentage patient new stroke ( ischemic hemorrhage ) 90 day .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Adult subject ( male female ≥18 year old ) Acute nondisabling ischemic stroke ( NIHSS ≤3 time randomization ) treat study drug within 24 hour symptoms onset . Symptom onset define `` last see normal '' principle TIA ( neurologic deficit attribute focal brain ischemia , resolution deficit within 24 hour symptom onset ) , treat investigational medication within 24 hour symptoms onset . Symptom onset define `` last see normal '' principle Informed consent sign Diagnosis hemorrhage pathology , vascular malformation , tumor , abscess major nonischemic brain disease , baseline head CT MRI scan mRS score &gt; 2 randomization ( premorbid historical assessment ) NIHSS ≥4 randomization Clear indication anticoagulation ( atrial fibrillation , mechanical cardiac valve , deep venous thrombosis , pulmonary embolism know hypercoagulable state ) Contraindication investigational medication Thrombolysis ischemic stroke within precede 7 day History intracranial hemorrhage Current treatment ( last dose give within 10 day randomization ) heparin therapy oral anticoagulation Gastrointestinal bleed major surgery within 3 month Planned likely revascularization ( angioplasty vascular surgery ) within next 3 month TIA minor stroke induce angiography surgery Severe noncardiovascular comorbidity life expectancy &lt; 3 month Women childbearing age practice reliable contraception document negative pregnancy test result Severe renal failure , define Glomerular Filtration Rate ( GFR ) &lt; 30 ml/min Severe hepatic insufficiency ( ChildPugh score B C )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>apixaban</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>aspirin</keyword>
	<keyword>new oral anticoagulant</keyword>
	<keyword>TIA</keyword>
	<keyword>acute minor ischemic stroke</keyword>
</DOC>